Валеология: Здоровье, Болезнь, Выздоровление. 2021; : 161-165
КОРОНАВИРУСНАЯ ИНФЕКЦИЯ И СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ
Аннотация
В настоящей статье сделан современный обзор литературы, посвященный проблеме сердечной недостаточности при COVID 19. Описаны основные и новейшие многоцентровые клинические исследования пациентов как ранее страдающими сердечной недостаточностью и присоединением коронавирусной инфекции, так и с приобретенной сердечной недостаточностью в результате коронавирусной инфекции.
Список литературы
1. Lai C. C., Shih T. P., Ko WC, Tang H. J., Hsueh P. R. (2020 Feb) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and co- rona virus disease-2019 (COVID-19): the epidemic and the chal-lenges. Int J Antimicrob Agents 17: 105924
2. COVID-19 Map [Internet] (2020) Johns Hopkins Coronavirus Resource Center. [cited 27 April 2020]. Available from: https://coronavirus.jhu.edu/map.html. Accessed 27 Apr 2020
3. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 3 March 2020 [Internet]. Who.int. (2020). Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [Internet]. Accessed 27 Apr 2020.
4. Novel C. P. (2020) The epidemiological characteristics of an out- break of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 41(2): 145
5. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
6. Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91–5.
7. Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., Huang H. (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 5 (7): 802–810.
8. Mehra M. R., Desai S. S., Kuy S., Henry T. D., Patel A. N. (2020) Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 382 (25): e102.
9. Ng T. M., Toews M. L. (2016) Impaired norepinephrine regulation of monocyte inflammatory cytokine balance in heart failure. World J Cardiol 8 (10): 584–589.
10. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Guan L. (2020) Clinical course and risk factors for mor- tality of adult inpatients with COVID-19 in Wuhan, China: a retro- spective cohort study. Lancet 395 (10229): 1054–1062.
11. Arentz M., Yim E., Klaff L., Lokhandwala S., Riedo F. X., Chong M., Lee M. (2020) Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 323 (16): 1612–1614.
12. Ruan Q., Yang K., Wang W., Jiang L., Song J. (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46 (5): 846–848.
13. Scally C., Abbas H., Ahearn T., Srinivasan J., Mezincescu A., Rudd A., Spath N., Yucel-Finn A., Yuecel R., Oldroyd K., Dospinescu C. (2019) Myocardial and systemic inflammation in acute stress-induced (Takotsubo) cardiomyopathy. Circulation 139 (13): 1581–1592.
14. Turner A. J., Hiscox J. A., Hooper N. M. ACE 2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004; 25: 291–4.
15. Oudit G. Y., Kassiri Z., Jiang C., et al. SARS-coronavirus modulation of myocardial ACE 2 expression and inflammation in patients with SARS. Eur J Clin Invest 2009; 39: 618–25.
16. Crackower M. A., Sarao R., Oudit G. Y., et al. Angiotensin converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822–8.
17. Gorodeski E. Z., Goyal P., Cox Z. L., Thibodeau J. T., Reay R. E., Rasmusson K., Rogers J. G., Starling R. C. (2020) Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the Heart Failure Society of America. J Card Fail 26 (6): 448– 456.
18. Abnousi F., Kang G., Giacomini J., Yeung A., Zarafshar S., Vesom N., Ashley E., Harrington R., Yong C. (2019) A novel noninvasive method for remote heart failure monitoring: the EuleriAn video Magnification aplications In heart Failure study (AMPLIFY). NPJ Digit Med 2 (1): 1–6.
19. Abraham W. T., Adamson P. B., Bourge R. C., Aaron M. F., Costanzo M. R., Stevenson L. W., Strickland W., Neelagaru S., Raval N., Krueger S., Weiner S., Shavelle D., Jeffries B., Yadav J. S. (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial [published correction appears in Lancet. 2012 Feb 4; 379 (9814): 412]. Lancet 377 (9766): 658–666.
20. Andersson C., Gerds T., Fosbøl E., Phelps M., Andersen J., Lamberts M., Holt A., Butt J. H., Madelaire C., Gislason G., Torp-Pedersen C. (2020) Incidence of new-onset and worsening heart failure before and after the COVID-19 epidemic lockdown in Denmark: a nationwide cohort study. Circ Heart Fail 13 (6): e007274.
Valeology: Health - Illnes - recovery. 2021; : 161-165
CORONAVIRUS INFECTION AND HEART INSUFFICIENCY
Abstract
This article provides a modern review of the literature on the problem of heart failure in COVID 19. Describes the main and latest multicenter clinical studies of patients, both with previously suffering from heart failure and the addition of coronavirus infection, and with acquired heart failure as a result of coronavirus infection.
References
1. Lai C. C., Shih T. P., Ko WC, Tang H. J., Hsueh P. R. (2020 Feb) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and co- rona virus disease-2019 (COVID-19): the epidemic and the chal-lenges. Int J Antimicrob Agents 17: 105924
2. COVID-19 Map [Internet] (2020) Johns Hopkins Coronavirus Resource Center. [cited 27 April 2020]. Available from: https://coronavirus.jhu.edu/map.html. Accessed 27 Apr 2020
3. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 3 March 2020 [Internet]. Who.int. (2020). Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [Internet]. Accessed 27 Apr 2020.
4. Novel C. P. (2020) The epidemiological characteristics of an out- break of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 41(2): 145
5. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
6. Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91–5.
7. Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., Huang H. (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 5 (7): 802–810.
8. Mehra M. R., Desai S. S., Kuy S., Henry T. D., Patel A. N. (2020) Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 382 (25): e102.
9. Ng T. M., Toews M. L. (2016) Impaired norepinephrine regulation of monocyte inflammatory cytokine balance in heart failure. World J Cardiol 8 (10): 584–589.
10. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Guan L. (2020) Clinical course and risk factors for mor- tality of adult inpatients with COVID-19 in Wuhan, China: a retro- spective cohort study. Lancet 395 (10229): 1054–1062.
11. Arentz M., Yim E., Klaff L., Lokhandwala S., Riedo F. X., Chong M., Lee M. (2020) Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 323 (16): 1612–1614.
12. Ruan Q., Yang K., Wang W., Jiang L., Song J. (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46 (5): 846–848.
13. Scally C., Abbas H., Ahearn T., Srinivasan J., Mezincescu A., Rudd A., Spath N., Yucel-Finn A., Yuecel R., Oldroyd K., Dospinescu C. (2019) Myocardial and systemic inflammation in acute stress-induced (Takotsubo) cardiomyopathy. Circulation 139 (13): 1581–1592.
14. Turner A. J., Hiscox J. A., Hooper N. M. ACE 2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004; 25: 291–4.
15. Oudit G. Y., Kassiri Z., Jiang C., et al. SARS-coronavirus modulation of myocardial ACE 2 expression and inflammation in patients with SARS. Eur J Clin Invest 2009; 39: 618–25.
16. Crackower M. A., Sarao R., Oudit G. Y., et al. Angiotensin converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822–8.
17. Gorodeski E. Z., Goyal P., Cox Z. L., Thibodeau J. T., Reay R. E., Rasmusson K., Rogers J. G., Starling R. C. (2020) Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the Heart Failure Society of America. J Card Fail 26 (6): 448– 456.
18. Abnousi F., Kang G., Giacomini J., Yeung A., Zarafshar S., Vesom N., Ashley E., Harrington R., Yong C. (2019) A novel noninvasive method for remote heart failure monitoring: the EuleriAn video Magnification aplications In heart Failure study (AMPLIFY). NPJ Digit Med 2 (1): 1–6.
19. Abraham W. T., Adamson P. B., Bourge R. C., Aaron M. F., Costanzo M. R., Stevenson L. W., Strickland W., Neelagaru S., Raval N., Krueger S., Weiner S., Shavelle D., Jeffries B., Yadav J. S. (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial [published correction appears in Lancet. 2012 Feb 4; 379 (9814): 412]. Lancet 377 (9766): 658–666.
20. Andersson C., Gerds T., Fosbøl E., Phelps M., Andersen J., Lamberts M., Holt A., Butt J. H., Madelaire C., Gislason G., Torp-Pedersen C. (2020) Incidence of new-onset and worsening heart failure before and after the COVID-19 epidemic lockdown in Denmark: a nationwide cohort study. Circ Heart Fail 13 (6): e007274.
